Galen medical journal · 2026
Severe Gastroparesis-like Syndrome Following Single-dose Liraglutide Administration: A Case Report : Short title: Severe Gastroparesis-like Syndrome Following Single-dose Liraglutide Administration.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
A Makkawy Eyad
Аннотация
BACKGROUND: As a GLP-1 analogue, liraglutide is given to patients as a treatment for both obesity and type 2 diabetes. It taken safely most of time, though there are also reports of effects on the digestive system.
CASE REPORT: In our case, a 30-year-old healthy female developed severe slowing of her stomach after a single injection of liraglutide (1 mg) for weight loss, without a doctor's care. Within a few hours of getting the treatment, the patient began having severe abdominal pain and kept vomiting. A thorough review using imaging and lab tests did not find anything wrong with her system to explain her symptoms. It points out that a single dose of liraglutide may result in major gastric motility problems for some patients. She recovered from her condition over two weeks with supportive care which eliminated her symptoms.
CONCLUSION: Further study is required to explain these reactions and to set up rules for safer use of GLP-1 receptor agonists outside the diabetic population.
CASE REPORT: In our case, a 30-year-old healthy female developed severe slowing of her stomach after a single injection of liraglutide (1 mg) for weight loss, without a doctor's care. Within a few hours of getting the treatment, the patient began having severe abdominal pain and kept vomiting. A thorough review using imaging and lab tests did not find anything wrong with her system to explain her symptoms. It points out that a single dose of liraglutide may result in major gastric motility problems for some patients. She recovered from her condition over two weeks with supportive care which eliminated her symptoms.
CONCLUSION: Further study is required to explain these reactions and to set up rules for safer use of GLP-1 receptor agonists outside the diabetic population.